QSAM - QSAM Biosciences receives patent in Europe for bone cancer treatment

2023-04-26 08:56:34 ET

• QSAM Biosciences ( OTCQB:QSAM ) announced the reception of a second patent from the European Patent Office. The patent safeguards the use of "lower specific activity" Samarium-153 when treating bone cancer in children and adults.
• This new patent in Europe covers the "high purity therapeutic bone agents" technology exclusively licensed to QSAM on a worldwide basis.
• The aforementioned process not only offers benefits like streamlined manufacturing, reduced costs, and logistical advantages but also effectively minimizes long-lived impurities such as Europium-154. As a result, it may enable higher and multiple dosing regimens for the treatment of various types of bone cancer, including those that have metastasized from organs such as the breast, lung, prostate, kidney, and others.
• Press Release

For further details see: